




ASCELIA PHARMA

ADVANCING ORPHAN ONCOLOGY

Share ticker: ACE
Nasdaq Stockholm

About Ascelia Pharma

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Global headquarters is in Malmö, Sweden.



MANGORAL® – Phase 3 liver contrast agent with no competition

Mangoral is a non-gadolinium oral contrast agent used for MRI-scans to improve visualisation of focal liver lesions (incl. liver metastases and primary liver cancer). Detecting liver metastases early is crucial for determining the right treatment method and thus the patient's chances of survival.


Mangoral targets patients with severely impaired kidney function who, due to the risk of serious, and potentially fatal, side effects cannot use the currently available contrast agents containing the heavy-metal gadolinium.

Mangoral has completed six Phase 1 and Phase 2 studies with strong clinical results and is currently in Phase 3. The ongoing pivotal Phase 3 study is a global multicentre study in up to 200 patients. First patient was enrolled in February 2020 and top-line results are expected in the second half of 2021.


The addressable market for Mangoral is estimated at \$500–600 million annually and Mangoral is expected to be the only product on the market for its patient segment. Mangoral has received Orphan Drug Designation from the US Food and Drug Administration (FDA).

Patient in the Phase 2 study

MRI without contrast agent (standard of care) – no metastases found




MRI with Mangoral Liver metastases clearly visible



ONCORAL – Phase 2 ready novel chemotherapy tablet

Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous (IV) high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is prepared for Phase 2.



COMPANY FACTS

Founded	2000
Headquarter	Malmö, Sweden
Stock Exchange	NASDAQ Stockholm
Stock ticker	ACE
Drug candidates	Mangoral® and Oncoral
Key Executives	Peter Benson, Chairman Magnus Corfitzen, CEO Carl Bjartmar, CMO Kristian Borbos, CFO Julie Waras Brogren, CCO

MARKET DATA (Dec 2020)

Market Cap	SEK 1,630 million
Shares Outstanding	28.7m
Top Shareholders	Sunstone Capital 15.6% CMC-SPV 10.2% Øresund Healthcare 7.0% Fjärde AP-fonden 4.9% Handelsbanken fonder 4.7% Healthinvest Partners 4.2%

KEY FINANCIALS

SEK million	2020 (9M)	2019 (9M)
EBIT	-65.5	-40.1
Net profit	-62.9	-38.9
Cash & Liquid assets	220.7	205.3
Equity	270.6	263.6
Operating Cash Flow	-58.0	-37.5

FINANCIAL CALENDAR

Feb 16, 2021	Full-year 2020 Financial Report
May 5, 2021	AGM
May 12, 2021	Q1-2021 Financial Report
Aug 19, 2021	Q2-2021 Financial Report
Nov 4, 2021	Q3-2021 Financial Report
Feb 10, 2022	FY 2021 Financial Report

CONTACTS

Mikael Widell Head of IR mw@ascelia.com M: +46 709 298 269	Kristian Borbos CFO kb@ascelia.com M: +46 735 179 113
--	---

Ascelia Pharma AB (publ)
Hyllie Boulevard, 215 32 Malmö, Sweden
www.ascelia.com